Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial

@article{Kutoh2012AlogliptinAA,
  title={Alogliptin as an initial therapy in patients with newly diagnosed, drug na{\"i}ve type 2 diabetes: a randomized, control trial},
  author={Eiji Kutoh and Yasuhiro Ukai},
  journal={Endocrine},
  year={2012},
  volume={41},
  pages={435-441}
}
The objectives of this study is to evaluate the efficacy and safety of alogliptin versus very low fat/calorie traditional Japanese diet (non-inferiority trial) as an initial therapy for newly diagnosed, drug naïve subjects with type 2 diabetes (T2DM). Study design was prospective, randomized, non-double-blind, controlled trial. The study was conducted at outpatient units of municipal hospital. Patients were newly diagnosed, drug naïve patients who visited the outpatient units. The patients… 
Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy
TLDR
Canagliflozin appears to offer clinically beneficial outcomes as an initial therapy in subjects with type 2 diabetes mellitus, although with certain adverse events.
Teneligliptin As an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes
TLDR
Glycemic efficacy of teneligliptin is obtained through activating beta-cell function as well as decreasing insulin resistance, and might be effectively and safely used as an initial therapy for newly diagnosed T2DM.
Effect of Pioglitazone on Serum Uric Acid Levels in Newly Diagnosed, Drug-Naïve Patients with Type 2 Diabetes
TLDR
While similar glycemic effects were observed, distinct regulations of UA and other diabetic parameters were observed with pioglitazone depending on the baseline UA levels, indicating that the level of UA together with other parameters might provide some diabetic characteristics of the subjects.
Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
TLDR
Clinical trial data with alogliptin demonstrate clinical efficacy in terms of glycosylated hemoglobin A1c and fasting plasma glucose reductions when used both as monotherapy and as a component of two- or three-drug combination regimens for the treatment of T2DM.
Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
TLDR
Results of the large, well designed EXAMINE trial revealed that alogliptin was not associated with an increased risk of major cardiovascular events in patients with type 2 diabetes and recent acute coronary syndrome and is a useful option for the treatment of patients withtype 2 diabetes.
US FDA APPROVED NEW DRUG ALOGLIPTIN: A DPP-4 INHIBITOR FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES
TLDR
Primary efficacy was A1C change from baseline with the high-dose combination (A25 + P30) versus each monotherapy, and alogliptin is well tolerated drug.
Comparison of the administration of teneligliptin every day versus every other day in Japanese patients with type 2 diabetes: A randomized non‐inferior test
TLDR
The administration of teneligliptin every other day had a similar efficacy, patient satisfaction level, and safety compared with its administration every day, and this information will be useful for reducing the economic load without changing the patients' satisfaction and glycemic control.
Alogliptin: a new dipeptidyl peptidase-4 inhibitor with potential anti-atherogenic properties
TLDR
Glycemic efficacy of alogliptin appears to be determined by the balance of its capacity in modulating insulin resistance and beta-cell function, and is closely linked to atherogenic lipids.
Alogliptin benzoate for the treatment of type 2 diabetes
TLDR
Alogliptin is a DPP-4 inhibitor that can help in improving glycemic control in patients with type 2 diabetes, including the elderly, and is generally well tolerated and does not increase the risk of hypoglycemia or weight gain.
Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.
  • U. A. Ndefo, O. Okoli, G. Erowele
  • Medicine, Biology
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2014
TLDR
Alogliptin, a selective D PP-4 inhibitor, does not differ greatly from the other DPP-4 inhibitors currently available and can be used as monotherapy or in combination with metformin for the management of type 2 diabetes.
...
1
2
3
...

References

SHOWING 1-10 OF 25 REFERENCES
Alogliptin: a review of its use in the management of type 2 diabetes mellitus.
TLDR
Oral alogliptin as monotherapy or in combination with other oral antihyperglycaemic agents or insulin therapy improved glycaemic control and was generally well tolerated in adult patients with inadequately controlled type 2 diabetes, including elderly patients.
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control
TLDR
Alogliptin monotherapy was well tolerated and significantly improved glycemic control in patients with type 2 diabetes, without raising the incidence of hypoglycemia.
Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series
  • E. Kutoh
  • Medicine
    Journal of medical case reports
  • 2011
TLDR
A novel hypothesis that the glycemic effects of this drug may be caused by mechanisms that are independent of the glucagon-like peptide 1 axis (extra-pancreatic effect) will be discussed.
Efficacy and safety of incretin based therapies: clinical trial data.
  • J. White
  • Medicine
    Journal of the American Pharmacists Association : JAPhA
  • 2009
TLDR
In addition to decreasing glycemia in type 2 diabetes, incretin therapies may improve other important parameters, including beta-cell function, blood pressure, and lipid levels, with a low risk for hypoglycemia.
Alogliptin: a new addition to the class of DPP-4 inhibitors
TLDR
Alogliptin causes significant reductions in HbA1c when used alone or in combination with other oral agents in patients with type 2 diabetes similar to other DPP-4 inhibitors in current clinical use.
Alogliptin for the treatment of type 2 diabetes.
  • J. White
  • Chemistry, Biology
    Drugs of today
  • 2011
TLDR
This manuscript will review alogliptin, its chemistry, pharmacokinetics/pharmacodynamics, drug interactions, clinical trials and its current state of FDA review.
Multifactorial intervention in Type 2 diabetes: The promise of incretin-based therapies
TLDR
Although GLP-1 agonists and DPP-4 inhibitors are at present not appropriate for primary treatment of cardiovascular risks factors, the reduction of these parameters is evidently beneficial.
[Diagnostic criteria for diabetes mellitus].
  • M. Tominaga
  • Medicine
    Rinsho byori. The Japanese journal of clinical pathology
  • 1999
TLDR
New diagnostic criteria for diabetes mellitus have been proposed by the American Diabetes Association, the World Health Organization consultation, and the Japan Diabetes Society, which established a new category of impaired fasting glucose (IFG) similar to impaired glucose tolerance (IGT) which is recognized by performing OGTT.
Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy - A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
TLDR
The development of new classes of blood glucose-lowering medications to supplement the older therapies, such as lifestyle-directed interventions, insulin, sulfonylureas, and metformin, has increased the number of treatment options available for type 2 diabetes, and practitioners are often left without a clear pathway of therapy to follow.
...
1
2
3
...